An antigen binding protein, wherein said antigen binding protein (i) comprises (a) a light chain variable domain comprising an amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NOs 461, 465 and 485, and (b) a heavy chain variable domain comprising an amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NOs: 459, 463, and 483; (ii) comprises the CDRL1, CDRL2, and CDRL3 sequence of SEQ ID NOs 461, 465 or 485, respectively, and the CDRH1, CDRH2, and CDRH3 sequence of SEQ ID NOs: 459, 463, or 483, respectively, wherein the CDRs are identified by the Kabat definition, the Chothia definition, the AbM definition or the contact definition; or (iii) comprises a CDRL1, CDRL2, and CDRL3 sequence encoded by a nucleic acid that selectively hybridizes to the nucleic acid encoding the CDRL1, CDRL2, and CDRL3 sequence of SEQ ID NOs: 461, 465 or 485, respectively; and a CDRH1, CDRH2, and CDRH3 sequence encoded by a nucleic acid that selectively hybridizes to the nucleic acid encoding the CDRH1, CDRH2, and CDRH3 sequence of SEQ ID NOs: 459, 463, or 483, respectively, wherein the CDRs are identified by the Kabat definition, the Chothia definition, the AbM definition or the contact definition; wherein the antigen binding protein specifically binds to human PCSK9, and wherein the antigen binding protein is an LDLR competitive neutralizing antigen binding protein. (i) comprises (a) a light chain variable domain comprising an amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NOs 461, 465 and 485, and (b) a heavy chain variable domain comprising an amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NOs: 459, 463, and 483; (a) a light chain variable domain comprising an amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NOs 461, 465 and 485, and (b) a heavy chain variable domain comprising an amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NOs: 459, 463, and 483; (ii) comprises the CDRL1, CDRL2, and CDRL3 sequence of SEQ ID NOs 461, 465 or 485, respectively, and the CDRH1, CDRH2, and CDRH3 sequence of SEQ ID NOs: 459, 463, or 483, respectively, wherein the CDRs are identified by the Kabat definition, the Chothia definition, the AbM definition or the contact definition; or (iii) comprises a CDRL1, CDRL2, and CDRL3 sequence encoded by a nucleic acid that selectively hybridizes to the nucleic acid encoding the CDRL1, CDRL2, and CDRL3 sequence of SEQ ID NOs: 461, 465 or 485, respectively; and a CDRH1, CDRH2, and CDRH3 sequence encoded by a nucleic acid that selectively hybridizes to the nucleic acid encoding the CDRH1, CDRH2, and CDRH3 sequence of SEQ ID NOs: 459, 463, or 483, respectively, wherein the CDRs are identified by the Kabat definition, the Chothia definition, the AbM definition or the contact definition; wherein the antigen binding protein specifically binds to human PCSK9, and wherein the antigen binding protein is an LDLR competitive neutralizing antigen binding protein.